The fact that checkpoint therapies can induce the appearance of autoimmune manifestations is not unexpected since there is extensive data available from knockout mice for CTLA-4 that develop a rapidly progressive lymphoproliferative autoimmune disease and CTLA-4 gene polymorphisms have been associated with an increased risk of autoimmune disease. This evidence concerns the gene CTLA4 and autoimmune disease.